Department of Anaesthesiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Department of Trauma Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Transfus Med. 2020 Apr;30(2):106-133. doi: 10.1111/tme.12659. Epub 2020 Jan 5.
The primary aim of this systematic review is to describe the effects of prehospital transfusion of red blood cells (PHTRBC) on patient outcomes. Damage control resuscitation attempts to prevent death through haemorrhage in trauma patients. In this context, transfusion of red blood cells is increasingly used by emergency medical services (EMS). However, evidence on the effects on outcomes is scarce. PubMed and Web of Science were searched through January 2019; 55 articles were included. No randomised controlled studies were identified. While several observational studies suggest an increased survival after PHTRBC, consistent evidence for beneficial effects of PHTRBC on survival was not found. PHTRBC appears to improve haemodynamic parameters, but there is no evidence that shock on arrival to hospital is averted, nor of an association with trauma induced coagulopathy or with length of stay in hospitals or intensive care units. In conclusion, PHTRBC is increasingly used by EMS, but there is no strong evidence for effects of PHTRBC on mortality. Further research with study designs that allow causal inferences is required for more conclusive evidence. The combination of PHTRBC with plasma, as well as the use of individualised transfusion criteria, may potentially show more benefits and should be thoroughly investigated in the future. The review was registered at Prospero (CRD42018084658).
本系统评价的主要目的是描述院前输注红细胞(PHTRBC)对患者结局的影响。损伤控制性复苏试图通过创伤患者的出血来预防死亡。在这种情况下,越来越多的急救医疗服务(EMS)使用输注红细胞。然而,关于其对结局影响的证据很少。通过检索 PubMed 和 Web of Science,截至 2019 年 1 月,共纳入了 55 篇文章。没有发现随机对照研究。虽然几项观察性研究表明 PHTRBC 后生存率增加,但没有发现 PHTRBC 对生存率有益影响的一致证据。PHTRBC 似乎可以改善血液动力学参数,但没有证据表明可以避免到达医院时的休克,也没有证据表明与创伤诱导的凝血障碍或住院时间或重症监护病房的停留时间有关。总之,EMS 越来越多地使用 PHTRBC,但没有强有力的证据表明 PHTRBC 对死亡率有影响。需要进一步进行允许因果推断的研究设计,以获得更确凿的证据。将 PHTRBC 与血浆联合使用,以及使用个体化输血标准,可能会显示出更多的益处,未来应进行深入研究。本综述已在 Prospero(CRD42018084658)上注册。